Aidoc Expands AI Service to X-ray, Receiving FDA 510(k) Clearance for Pneumothorax

Aidoc, the leading provider of healthcare AI solutions, today announced that it received FDA 510(k) clearance for its triage and notification of pneumothorax on X-ray exams.

Aiodic notes, a one-stop partner for the enterprise’s clinical AI needs, Aidoc’s other seven FDA-cleared solutions are already implemented across U.S. health systems, flagging and communicating suspected pathologies in CT exams – and now have expanded to the high volume X-ray modality.

Aidoc’s newly FDA-cleared solution runs on all X-ray machines including portable ones, and is designed to analyze X-ray images. It automatically flags positive cases of pneumothorax, facilitating physicians to read X-rays in a timely manner.

The ability to quickly identify pneumothorax is imperative as it can worsen rapidly and result in respiratory or cardiac failure. This however is easier said than done, due to the extensive imaging volumes radiologists have to continuously examine. Aidoc’s highly accurate AI pneumothorax algorithm addresses this challenge by analyzing X-rays, flagging, and notifying physicians of the suspected findings.

“We’re very excited about this important milestone,” said Elad Walach, CEO of Aidoc. “This FDA clearance further validates the breadth of our AI platform, going beyond specific AI algorithms to act as a healthcare AI hub for the enterprise’s cross-specialty needs. This includes ER, ICU, outpatient centers, inpatient admissions, and the coordination of care and communication among providers. By bringing radiologists and proceduralists to the same AI platform, we enable enhanced collaboration across departments and systems to deliver patients with the right treatment at the right time.”

Aidoc’s AI platform processes high volumes of scans and images without disrupting the physician’s workflow. Existing partners of Aidoc, who add the pneumothorax solution to their portfolio, will not require any additional integration, infrastructure, or maintenance efforts.

 

SourceAidoc,

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version